Literature DB >> 20715167

Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study.

Valery E Lemmens1, Yvonne L Klaver, Vic J Verwaal, Harm J Rutten, Jan Willem W Coebergh, Ignace H de Hingh.   

Abstract

The aim of our study was to provide population-based data on incidence and prognosis of synchronous peritoneal carcinomatosis and to evaluate predictors for its development. Diagnosed in 1995-2008, 18,738 cases of primary colorectal cancer were included. Predictors of peritoneal carcinomatosis were analysed by multivariable logistic regression analysis. Median survival in months was calculated by site of metastasis. In the study period, 904 patients were diagnosed with synchronous peritoneal carcinomatosis (4.8% of total, constituting 24% of patients presenting with M1 disease). The risk of peritoneal carcinomatosis was increased in case of advanced T stage [T4 vs. T1,2: odds ratio (OR) 4.7, confidence limits 4.0-5.6), advanced N stage [N0 vs. N1,2: OR 0.2 (0.1-0.2)], poor differentiation grade [OR 2.1 (1.8-2.5)], younger age [<60 years vs. 70-79 years: OR 1.4 (1.1-1.7)], mucinous adenocarcinoma [OR 2.0 (1.6-2.4)] and right-sided localisation of primary tumour [left vs. right: OR 0.6 (0.5-0.7)]. Median survival of patients with peritoneum as single site of metastasis remained dismal [1995-2001: 7 (6-9) months; 2002-2008: 8 (6-11) months], contrasting the improvement among patients with liver metastases [1995-2001: 8 (7-9) months; 2002-2008: 12 (11-14) months]. To conclude, synchronous peritoneal metastases from colorectal cancer are more frequent among younger patients and among patients with advanced T stage, mucinous adenocarcinoma, right-sided tumours and tumours that are poorly differentiated. The prognosis of synchronous peritoneal carcinomatosis remains poor with a median survival of 8 months and even worse if concomitant metastases in other organs are present.
Copyright © 2010 UICC.

Entities:  

Mesh:

Year:  2010        PMID: 20715167     DOI: 10.1002/ijc.25596

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  100 in total

1.  Oxaliplatin and molecular-targeted drug therapies improved the overall survival in colorectal cancer patients with synchronous peritoneal carcinomatosis undergoing incomplete cytoreductive surgery.

Authors:  T Adachi; T Hinoi; H Egi; M Shimomura; H Ohdan
Journal:  Surg Today       Date:  2014-08-26       Impact factor: 2.549

2.  EUS-derived criteria for distinguishing benign from malignant metastatic solid hepatic masses.

Authors:  Larissa L Fujii-Lau; Barham K Abu Dayyeh; Marco J Bruno; Kenneth J Chang; John M DeWitt; Paul Fockens; David Forcione; Bertrand Napoleon; Laurent Palazzo; Mark D Topazian; Maurits J Wiersema; Amitabh Chak; Jonathan E Clain; Douglas O Faigel; Ferga C Gleeson; Robert Hawes; Prasad G Iyer; Elizabeth Rajan; Tyler Stevens; Michael B Wallace; Kenneth K Wang; Michael J Levy
Journal:  Gastrointest Endosc       Date:  2015-02-07       Impact factor: 9.427

Review 3.  Oligometastatic Disease in the Peritoneal Space with Gastrointestinal Cancer.

Authors:  Beate Rau; Andreas Brandl; Andreas Pascher; Wieland Raue; Paul Sugarbaker
Journal:  Visc Med       Date:  2017-02-10

Review 4.  [Prognostic biomarkers for metastatic colorectal cancer].

Authors:  J H L Neumann
Journal:  Pathologe       Date:  2016-11       Impact factor: 1.011

5.  Long-term results after proactive management for locoregional control in patients with colonic cancer at high risk of peritoneal metastases.

Authors:  P Sammartino; S Sibio; D Biacchi; M Cardi; P Mingazzini; M S Rosati; T Cornali; B Sollazzo; J Maherfouad Atta; A Di Giorgio
Journal:  Int J Colorectal Dis       Date:  2014-07-01       Impact factor: 2.571

Review 6.  Systemic therapy in addition to cytoreduction and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: recent insights from clinical studies and translational research.

Authors:  Checca Bakkers; Geert A A M Simkens; Ignace H J T De Hingh
Journal:  J Gastrointest Oncol       Date:  2021-04

Review 7.  Hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis: a clinical pharmacological perspective on a surgical procedure.

Authors:  Loek A W de Jong; Fortuné M K Elekonawo; Philip R de Reuver; Andre J A Bremers; Johannes H W de Wilt; Frank G A Jansman; Rob Ter Heine; Nielka P van Erp
Journal:  Br J Clin Pharmacol       Date:  2018-10-25       Impact factor: 4.335

Review 8.  Regulation of osmolality for cancer treatment.

Authors:  Atsushi Shiozaki; Daisuke Ichikawa; Toshiyuki Kosuga; Yoshinori Marunaka; Eigo Otsuji
Journal:  J Physiol Sci       Date:  2017-02-10       Impact factor: 2.781

9.  Should isolated peritoneal carcinomatosis from colorectal cancer be sub-classified into stage IVB in era of modern chemotherapy?

Authors:  H Ishida; K Kumamoto; K Ishibashi; S Hatano; T Matsuzawa; N Okada; Y Kumagai; H Baba; N Haga
Journal:  Tech Coloproctol       Date:  2013-02-07       Impact factor: 3.781

10.  Intraoperative radiotherapy and cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Five consecutive case reports of locally advanced rectal cancer with synchronous peritoneal carcinomatosis.

Authors:  Y L B Klaver; V E P P Lemmens; S W Nienhuijs; G A P Nieuwenhuijzen; H J T Rutten; I H J T de Hingh
Journal:  Strahlenther Onkol       Date:  2013-01-19       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.